Scarica l'app Stockscreener
217.11
3.79%
-8.55
Dopo l'orario di chiusura:
217.40
0.29
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AMD, AbbVie, Boston Scientific, Eli Lilly, MP, Super Micro, Palantir, and More Movers - Barron's
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail
AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum - MSN
AbbVie stock slides as investors focus on aesthetics weakness - Crain's Chicago Business
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth - Benzinga
AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq - Seeking Alpha
AMD, AbbVie, Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More Movers - Barron's
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs - marketscreener.com
Eli Lilly, Novo Nordisk, AbbVie: Pharma earnings roundup - Yahoo Finance
ABBV Forecasts Revenue Boost with Favorable Currency Impact - GuruFocus
Earnings call transcript: AbbVie Q4 2025 beats earnings estimates, stock dips - Investing.com
Q4 Earnings Summary: Eli Lilly and AbbVie Beat, Uber Mixed - Investing.com
AbbVie's (ABBV) Growth Prospects Show Strong Momentum - GuruFocus
AbbVie's (ABBV) Anticipated Q1 Revenue Falls Short of Market Exp - GuruFocus
AbbVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
AbbVie Raises 2026 Earnings Forecast as Botox Sales Rebound - Bloomberg.com
AbbVie (ABBV) Stock: Slides 6.5% Despite Strong Revenue Growth and 2026 Outlook - CoinCentral
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
These Stocks Are Today’s Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More - Barron's
AbbVie (ABBV) Projects Strong Financial Outlook for Fiscal Year 2026 - GuruFocus
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's
ABBV Plans Continued Investment in Under-Explored Aesthetics Mar - GuruFocus
ABBV Poised for Strong Revenue Growth Through 2029 - GuruFocus
ABBV: Strong Position to Innovate and Positive Business Outlook - GuruFocus
AbbVie's (ABBV) 2026 Profit Forecast Exceeds Wall Street Expecta - GuruFocus
AbbVie (ABBV) Surpasses Earnings and Revenue Expectations - GuruFocus
AbbVie (ABBV) Reports Strong Q4 Earnings, Beating Expectations - GuruFocus
AbbVie (ABBV) Surpasses Q4 Expectations with Strong Humira Sales - GuruFocus
AbbVie (ABBV) Surpasses Q4 Expectations with Strong Earnings - GuruFocus
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates - Yahoo! Finance Canada
AbbVie: Q4 Earnings Snapshot - The Pantagraph
AbbVie Revenue Rises on Immunology Growth - The Wall Street Journal
AbbVie (ABBV) Exceeds Revenue Expectations in Q4 - GuruFocus
AbbVie's 2026 EPS Guidance Excludes Potential IPR&D and Milestone Impacts - GuruFocus
AbbVie beats Q4 expectations, shares dip - Yahoo Finance
AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue - The Globe and Mail
AbbVie stock slips despite Q4 beat (ABBV:NYSE) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss - Chartmill
AbbVie Slumps Despite Quarterly Beat, Solid Guidance - Investor's Business Daily
AbbVie's (NYSE:ABBV) Q4 CY2025: Beats On Revenue - Finviz
(ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27 - marketscreener.com
Earnings Flash (ABBV) AbbVie Posts Q4 Net Revenue $16.62B, vs. FactSet Est of $16.41B - marketscreener.com
Earnings Flash (ABBV) AbbVie Posts Q4 Adjusted EPS $2.71, vs. FactSet Est of $2.65 - marketscreener.com
AbbVie beats Q4 expectations, shares dip By Investing.com - Investing.com South Africa
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss - marketscreener.com
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results - TradingView
AbbVie earnings beat by $0.06, revenue topped estimates By Investing.com - Investing.com South Africa
AbbVie Q4 revenue beats expectations on immunology growth - TradingView
AbbVie earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Earnings Scheduled For February 4, 2026 - Benzinga
AlphaQuest LLC Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
Savant Capital LLC Has $42.96 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Healthcare Stocks Show Dividend Growth Potential - Intellectia AI
AbbVie: Q4 Financial Highlights - Bitget
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next - TechStock²
Veteran AbbVie worker accuses company of sidelining her for younger staff - HRD America
AbbVie (ABBV) Set for Earnings Surge with Key Developments Ahead - GuruFocus
AbbVie Q4 Preview: Here's what to expect - Seeking Alpha
A Preview Of AbbVie's Earnings - Benzinga
AbbVie Seeks FDA Approval for Vitiligo Treatment - marketscreener.com
AbbVie (ABBV) Seeks FDA and EMA Approval for Rinvoq in Treating Vitiligo - GuruFocus
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Adults and Adolescents With Vitiligo - Investing News Network
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program - AbbVie News Center
AbbVie submits regulatory applications to FDA and EMA for upadacitinib in vitigo - TipRanks
AbbVie (ABBV) Seeks New Indication Approval for Upadacitinib in Vitiligo - GuruFocus
AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion - Yahoo Finance
AbbVie petitions US and EU to clear first systemic drug for vitiligo - stocktitan.net
Callan Family Office LLC Has $9.58 Million Position in AbbVie Inc. $ABBV - MarketBeat
2.15%
6.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):